Matt Orton of Raymond James Investment suggests fears of a US recession due to tariffs are exaggerated. He believes the rally in India is sustainable, with potential benefits from quickly negotiated tariffs. Investors should look for high-quality opportunities after April 2nd. China may face tougher tariffs, but this could lead to beneficial negotiations.
5 pharma stks with upside potential of up to 12%
Nifty Pharma index has moved in tandem with the headline index, with nearly 5% returns in the last month, with stocks gaining by up to
June 12, 2025